Diplomat Pharmacy Q1 EPS Misses Street View

Diplomat Pharmacy (DPLO), a provider of specialty pharmacy services, reported Q1 earnings that missed, but revenue that topped Wall Street expectations, and it boosted its full-year revenue outlook.

Adjusted EPS increased to $0.20 in the March quarter, from $0.19 a year earlier, but missed the $0.22 average estimate of analysts surveyed by Capital IQ.

Q1 revenue increased 24% to $1.342 billion, surpassing the analyst consensus of $1.282 billion.

Moving forward, the company now anticipates FY18 revenue in the range of $5.5 and $5.9 billion, up from its previous revenue guidance of $5.3 billion to $5.6 billion. Analysts had projected $5.44 billion.

The company expects FY18 EPS in the range of $0.87 to $0.97. Analysts had projected $0.92.

Leave a Reply

Your email address will not be published. Required fields are marked *